Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1

Conditions

Solid Tumor Cancer 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × SB 743921 × Clear all
NCT00343564 2020-01-13

A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Cytokinetics

Phase 1/2 Completed
68 enrolled 26 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT00136513 2008-10-16

SB-743921 In Patients With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
30 enrolled
Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡